RheumNow

#2660 In >8000 women, serum urate rose sharply during the menopausal transition, then plateaued after menopause. Hype https://pbs.twimg.com/profile_images/1489576716322447363/HmrVJtAH_normal.jpg john+RNV2@john… Wed, […]

#ACR25 Please find my video summary on the Phase 3 RCTs results of Ianalumab in moderate to severe disease activity

#2659 In a large real-world target trial (>1.3M with T2D), SGLT2 inhibitors, esp dapagliflozin & empagliflozin, w https://pbs.twimg.com/profile_images/1489576716322447363/HmrVJtAH_normal.jpg john+RNV2@john… Wed,

In PsA patients, GLP-1 RA therapy led to significant weight loss and improvements in CRP, pain, lipids, and blood pressu

Abstract 2697: Compared to MMF, tacrolimus showed – similar SRR by week 96 (58.5% vs. 69.2%, OR 0.62; 95% CI

The next VEXAS, but also maybe we can treat it? IDH1/2 Another clonal hematopoesis known to cause heme malignancy, but

Ph2B RCT of Rosnilimab Tcell depleter (PD-1high Tph/Tfh, Teff) Wk 12 Primary Endpoint met Mean change DAS28-CRP at Wk 1

#ACR25 Abstr#LB21 Are they novel somatic variants beyond #VEXAS in driving inflammation in undiagnosed SAID?Unbiased enr https://pbs.twimg.com/profile_images/1625445768768135171/M24lCgC__normal.jpg john+RNV2@john… Wed, 10/29/2025

#ACR25 Abstr#LB20 At EULAR, data for Phase 3 RCT of Deucravacitinib, Tyk2-i in active #PsA showed ACR20 was met at

Not all RA meds are equal for the heart. In >10K older adults w/ RA, advanced therapies lowered MACE risk

POETYK PsA 1 and 2 Deucravacitinib TYK2 inhibitor Ph3 RCT 52 wks data Deucra 336pts PBO 334pts then crossover wk

POETYK PsA-1 (one of paired deucravacitinib in PsA ph3 registration studies) Oral med Good outcomes Safety very good https://pbs.twimg.com/profile_images/1659729373426241536/tnA2hRe4_normal.jpg john+RNV2@john…

Questions #ACR25 LB20 to Paul Emery on rosnilimab: Fleischmann: could be induction therapy? (Not intent, but could be) C https://pbs.twimg.com/profile_images/1659729373426241536/tnA2hRe4_normal.jpg

In POETYK PsA-1, deucravacitinib showed sustained efficacy through Week 52 in PsA, improving joint, skin, PROs, and radi https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg john+RNV2@john…

Mease et al. 52 week results deucravacitinib in PsA. Approx ACR20 60%, ACR50 40%, ACR70 25%. Sustained radiographic bene https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3_normal.jpg

Upadacitinib: revisiting safety data in RA and GCA mrinalini.dey@… Wed, 10/29/2025 – 08:23

IgG4: Rare, but new treatments on the horizon Janet.Pope@sjh… Wed, 10/29/2025 – 08:39

Secrets and Pearls in Rheumatology https://t.co/SwnlB8UbHO @Janetbirdope pearls in rheumatology. Sero negative infl https://pbs.twimg.com/profile_images/1974180952390721536/r5ej4z9M_normal.jpg john+RNV2@john… Wed, 10/29/2025 – 07:25 NoufAhmedAlham2

Day 3 Recap- ACR Convergence 2025 Highlights https://t.co/4ZiTWVVwhl The analogy used by @RheumNow to explain differe https://pbs.twimg.com/profile_images/1974180952390721536/r5ej4z9M_normal.jpg john+RNV2@john… Wed, 10/29/2025

What’s the latest in PsA? https://t.co/I8ZgRQpVy6 Great review for whats new in PsA by @drpnash Looking forward for https://pbs.twimg.com/profile_images/1974180952390721536/r5ej4z9M_normal.jpg john+RNV2@john…

Secukinumab vs Ustekinumab in PsA https://t.co/EylYHtRWsj @synovialjoints Elaborate more on head to head trial in https://pbs.twimg.com/profile_images/1974180952390721536/r5ej4z9M_normal.jpg john+RNV2@john… Wed, 10/29/2025 –